FDA warning and removal of rosiglitazone from VA national formulary

American Journal of Managed Care

Volumn 19, Issue 9, 2013, Pages 748-758

  Aspinall, Sherrie L ^a,b,c   Zhao, Xinhua ^a,b   Good, Chester B ^a,b,c,d   Stone, Roslyn A ^b,e   Smith, Kenneth J ^c   Cunningham, Francesca E ^a  

^a VA Center for Medication Safety   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ROSIGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT;

ARTICLE; COHORT ANALYSIS; DRUG FORMULARY; FOOD AND DRUG ADMINISTRATION; HUMAN; PRESCRIPTION; PRIORITY JOURNAL; VETERANS AFFAIRS NATIONAL FORMULARY; DRUG RECALL; FEMALE; GOVERNMENT; MALE; PUBLICATION; STATISTICAL MODEL; UNITED STATES;

COHORT STUDIES; FEMALE; FORMULARIES AS TOPIC; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MODELS, STATISTICAL; SAFETY-BASED DRUG WITHDRAWALS; THIAZOLIDINEDIONES; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84887256441     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. US Food and Drug Administration. Information for healthcare professionals Rosiglitazone maleate (marketed as Avandia, Avandamet, and Avandaryl). http://www.fda.gov/Drugs/DrugSafety/Postmarket- DrugSafetyInformationforPatientsandProviders/ucm143460.htm. Published May 21, 2007. Accessed December 7, 2009.
2. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007; 356(24):2457-2471.
3. published correction appears in N Engl J Med. 2007;357(1):100
4. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone. JAMA. 2007;298(10):1189-1195.
5. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a metaanalysis of randomized trials. JAMA. 2007;298(10):1180-1188.
6. Lipscombe LL, Gomes T, Lévesque LE, Hux JE, Juurlink DN, Alter DA. Thiazolidinediones and cardiovascular outcomes on older patients with diabetes. JAMA. 2007;298(22):2634-2643.
7. Miller DR, Christiansen C, Palnatti M, LaFrance JP, Cunningham F. Cardiovascular disease risks with rosiglitazone and pioglitazone usein US Veterans. Abstracts of the 24th International Conference on Pharmacoepidemiology and Therapeutic Risk Management. Pharmacoepidemiol Drug Saf. 2008;17:S1-S294.
8. Jain R, Mullins CD, Lee H, Wong W. Use of rosiglitazone and pioglitazone immediately after the cardiovascular risk warnings. Res Social Adm Pharm. 2012;8(1):47-59.
9. Morrow RL, Carney G, Wright JM, Bassett K, Sutherland J, Dormuth CR. Impact of rosiglitazone meta-analysis on use of glucose-lowering medications. Open Med. 2010;4(1):e50-e59.
10. Orrico KB, Lin JK, Wei A, Yue H. Clinical consequences of disseminating the rosiglitazone FDA safety warning. Am J Manag Care. 2010;16(5):e111-e116.
11. Shi L, Zhao Y, Szymanski K, Yau L, Fonseca V. Impact of thiazolidinedione safety warnings on medication use patterns and glycemic control among veterans with diabetes mellitus. J Diabetes Complications. 2011;25:143-150.
12. Starner CI, Schafer JA, Heaton AH, Gleason PP. Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events. J Manag Care Pharm. 2008;14(3):523-531.
13. Carroll NV. How effectively do managed care organizations influence prescribing and dispensing decisions? Am J Manag Care.2002;8(12):1041-1054.
14. Brooks TC, Burlingame M, Burk M, et al. Travoprost: a prostaglandin analogue for the treatment of glaucoma. Formulary (Cleveland, Ohio). 2009;44:322-328.
15. Nelson WW, Vrmeulen LC, Geurkink EA, Ehlert DA, Reichelderfer. Clinical and humanistic outcomes in patients with gastroesophageal reflux disease converted from omeprazole to lansoprazole. Arch Intern Med. 2000;160(16):2491- 2496.
16. Yeaw J, Benner JS, Wait JG, Sian S, Smith DB. Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm. 2009;15(9):728-740.
17. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613-619.
18. Aspinall SL, Zhao X, Good CB, et al. Intervention to decrease glyburide use in elderly patients with renal insufficiency. Am J Geriatr Pharmacother. 2011;9(1):58-68.
19. US Food and Drug Administration. Information for healthcare professionals Rosiglitazone maleate (marketed as Avandia, Avandamet, and Avandaryl). http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm143406.htm#2007-5. Updated November 19, 2007. Accessed January 26, 2012.
20. Huskamp HA, Epstein AM, Blumenthal D. The impact of a national prescription drug formulary on prices, market share, and spending: lessons for Medicare? Health Aff (Millwood). 2003;22(3):149-158.
21. Patel H, Toe DC, Burke S, Rasu RS. Anticonvulsant use after formulary status change for brand-name second-generation anticonvulsants. Am J Manag Care. 2010;16(8):e197-e204.
22. Little RR, Rohlfing CL, Sacks DB; National Glycohemoglobin Standardization Program (NGSP) Steering Committee. Status of hemoglobin A1c measurement and goals for improvement: from chaos to order for improving diabetes care. Clin Chem. 2011;57(2):205-214.